NanoViricides, Inc. NEW (NNVC) News
Filter NNVC News Items
NNVC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest NNVC News From Around the Web
Below are the latest news stories about Nanoviricides Inc that investors may wish to consider to help them evaluate NNVC as an investment opportunity.
NanoViricides (NYSEAMERICAN:NNVC) Issues Earnings ResultsNanoViricides (NYSEAMERICAN:NNVC) issued its earnings results on Monday. The company reported ($0.23) EPS for the quarter, missing the Zacks consensus estimate of ($0.20) by ($0.03), Fidelity Earnings reports. Shares of NNVC stock opened at $4.76 on Thursday. The stock has a market capitalization of $54.81 million, a price-to-earnings ratio of -5.88 and a beta of [] |
NanoViricides, Inc. (NYSEAMERICAN:NNVC) Short Interest UpdateNanoViricides, Inc. (NYSEAMERICAN:NNVC) was the target of a large drop in short interest in October. As of October 29th, there was short interest totalling 494,500 shares, a drop of 36.4% from the October 14th total of 777,000 shares. Currently, 4.5% of the companys stock are short sold. Based on an average trading volume of 2,500,000 [] |
NanoViricides, Inc.: NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical TrialsSHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel n |
NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical TrialsSHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), has filed its quarterly report for its first quarter of financial year 2022 with the Securities and Exchange Commission. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWelcome back, trader! |
NanoViricides, Inc.: NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2SHELTON, CT / ACCESSWIRE / November 15, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomed |
EXCLUSIVE: NanoViricides Completes Oral Gummies, Lung Inhalation Formulations For COVID-19 TreatmentNanoViricides, Inc. (NYSE: NNVC) announced Monday it has developed an oral gummies formulation of its COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients. The company believes the formulation may have advantages in terms of drug bioavailability over oral pills, because of partial sublingual absorption that avoids the gastrointestinal tract. What To Know: NanoViricides says this oral gummies formulation would be attractive to patients, especially children, over oral pills. The c |
NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2SHELTON, CT / ACCESSWIRE / November 15, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, announced today that it has developed oral gummies formulations of its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients. |
EXCLUSIVE: NanoViricides Develops Chewable Pills, Lung Inhalation Formulations For COVID-19 CandidateNanoViricides Inc (NYSE: NNVC) has developed oral gummies formulations of its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients. What Happened: NanoViricides completed the development of an oral gummies (chewable gel) formulation of NV-CoV-2 for the benefit of symptomatic non-hospitalized patients. The Company believes that this formulation may have advantages in drug bioavailability over oral pills because of partial sublingual absorption that avoids the gast |
NanoViricides Inc. (AMEX: NNVC): Is It Stable And Growing?NanoViricides Inc. (AMEX:NNVC) shares, rose in value on Friday, 11/05/21, with the stock price down by -11.92% to the previous days close as strong demand from buyers drove the stock to $4.73. Actively observing the price movement in the last trading, the stock closed the session at $5.37, falling within a range of $4.71 and NanoViricides Inc. (AMEX: NNVC): Is It Stable And Growing? Read More » |